Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
FAQs

The Key of Stability Studies in Phase I and Phase III Clinical Trials

Phase I clinical 

 ◆ Stability data should support the formulation to meet the requirements during the clinical study

Phase III clinical trials 

 ◆ Use currently prepared products for compatibility stability studies

 ◆ Use Multi-dose packaging (except solid oral formulations) to provide the necessary stability after package opening 

 ◆ To ensure sufficient stability data in NDA, it is recommended to provide a formal stability study program